Shelly Erickson
Family · Gilbert, AZNPI 1124543244
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $9,934 of the $13,006 with a category attached, or 76.4%. Roche Products Limited accounts for 78.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $10,748 and has fallen 97.4% since, to $276 in 2025. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $206.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$10K
- Seagen Inc.$1K
- Gilead$808
- Stemline Therapeutics Inc.$351
- AstraZeneca$294
- Pfizer$186
- plus $143 from 3 others
What the payments were for
- Travel & lodging$9,93476%
- Food & beverage$2,67621%
- Education$3963%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 4 | $10,211 |
| Seagen Inc. | 23 | $1,012 |
| Gilead | 12 | $808 |
| Stemline Therapeutics Inc. | 5 | $351 |
| AstraZeneca | 5 | $294 |
| Pfizer | 8 | $186 |
| Merck | 3 | $61 |
| Tersera Therapeutics LLC | 2 | $60 |
| Lilly USA, LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,006 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 26 | $4,702 |
| Letrozole | 136 | $4,074 |
| Anastrozole | 179 | $3,807 |
| Ibandronate Sodium | 28 | $1,042 |
| Tamoxifen Citrate | 28 | $1,005 |
| Pregabalin | 20 | $391 |
| Duloxetine Hcl | 13 | $325 |
| Gabapentin | 18 | $263 |
| Potassium Chloride | 16 | $216 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $159 |
| Alendronate Sodium | 20 | $125 |
| Lorazepam | 11 | $36 |
Paid to pharmacies, not to this prescriber.
Other family in Gilbert
- Celeste FineGilbert$82K
- Rechelle TrejoGilbert$34K
- Jonathan HenriquezGilbert$26K
- Arin LamoureauxGilbert$17K
- Sharon MagalonaMesa$441K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Lindsay CarterTucson$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.